„Previous success can be a big handicap,“ says biotech visionary Jean-Paul Clozel
When Jean-Paul Clozel sold his biotech firm Actelion to Johnson & Johnson for USD 30 billion last year, it was the biggest European pharma deal in more than a decade and made him and his wife Martine, the co-founder, instant billionaires. But instead of resting on his laurels, Clozel immediately founded a new company, Idorsia, which develops drugs to treat insomnia, lupus, and other diseases. In the Executive Talk, he tells Editor in Chief Urs Gredig why he’s in it for the long run and why his love of science is at the core of everything he does.
Monika Walser, de Sede CEO: „It’s not always easy with me“
Monika Walser is not a woman who beats around the bush. The CEO of the Swiss furniture manufacturer de Sede and former head of the iconic brand Freitag prefers to be direct. Since arriving at de Sede four years ago, she has led the indebted company back into the black. How did she manage that „open heart surgery“ as she puts it, and how does her team react to her straightforward leadership tactics? Find out in this week’s Executive Talk with editor in chief Urs Gredig.
„I was never a public figure; I don’t need the limelight“
Peter Voser has been called the quiet star among Swiss business leaders. The man who left school at 16 to do an apprenticeship may be known as soft-spoken, but he’s arguably the most successful Swiss CEO of the last two decades. As head of Shell, he was rumored to be Europe’s best paid executive, and as chairman of the board of ABB, he’s now instrumental in defining the strategy for the Swiss engineering conglomerate. The avid football fan talks to CNNMoney Switzerland’s editor in chief Urs Gredig about the big pay, big dreams, and big challenges of being a top manager.